Ulunar Breezhaler

Country: European Union

Language: Slovenian

Source: EMA (European Medicines Agency)

Buy It Now

Active ingredient:

Glycopyrronium bromid, indacaterol maleate

Available from:

Novartis Europharm Limited

ATC code:

R03AL04

INN (International Name):

indacaterol, glycopyrronium bromide

Therapeutic group:

Zdravila za obstruktivne pljučne bolezni,

Therapeutic area:

Pljučna bolezen, kronična obstruktivna bolezen

Therapeutic indications:

Zdravilo Ulunar Breezhaler je indicirano za zdravljenje bronhodilatatorjev za vzdrževanje simptomov pri odraslih bolnikih s kronično obstruktivno pljučno boleznijo (KOPB).

Product summary:

Revision: 14

Authorization status:

Pooblaščeni

Authorization date:

2014-04-23

Patient Information leaflet

                                30
8.
DATUM IZTEKA ROKA UPORABNOSTI ZDRAVILA
Uporabno do
Inhalator vsakega pakiranja je treba zavreči, ko porabite vse kapsule
tega pakiranja.
9.
POSEBNA NAVODILA ZA SHRANJEVANJE
Shranjujte pri temperaturi do 25 °C.
Kapsule shranjujte v originalnem pretisnem omotu, da jih zaščitite
pred vlago, in jih vzemite iz
ovojnine šele tik pred uporabo.
10.
POSEBNI VARNOSTNI UKREPI ZA ODSTRANJEVANJE NEUPORABLJENIH
ZDRAVIL ALI IZ NJIH NASTALIH ODPADNIH SNOVI, KADAR SO POTREBNI
11.
IME IN NASLOV IMETNIKA DOVOLJENJA ZA PROMET Z ZDRAVILOM
Novartis Europharm Limited
Vista Building
Elm Park, Merrion Road
Dublin 4
Irska
12.
ŠTEVILKA(E) DOVOLJENJA (DOVOLJENJ) ZA PROMET
EU/1/14/917/001
6 kapsul + 1 inhalator
EU/1/14/917/007
10 kapsul + 1 inhalator
EU/1/14/917/002
12 kapsul + 1 inhalator
EU/1/14/917/003
30 kapsul + 1 inhalator
EU/1/14/917/004
90 kapsul + 1 inhalator
13.
ŠTEVILKA SERIJE
Serija
_ _
14.
NAČIN IZDAJANJA ZDRAVILA
Predpisovanje in izdaja zdravila je le na recept.
15.
NAVODILA ZA UPORABO
16.
PODATKI V BRAILLOVI PISAVI
Ulunar Breezhaler
31
17.
EDINSTVENA OZNAKA – DVODIMENZIONALNA ČRTNA KODA
Vsebuje dvodimenzionalno črtno kodo z edinstveno oznako.
18.
EDINSTVENA OZNAKA – V BERLJIVI OBLIKI
PC
SN
NN
32
PODATKI NA ZUNANJI OVOJNINI
ZUNANJA ŠKATLA SKUPNEGA PAKIRANJA (VKLJUČNO Z “BLUE BOX”
PODATKI)
1.
IME ZDRAVILA
Ulunar Breezhaler 85 mikrogramov/43 mikrogramov prašek za
inhaliranje, trde kapsule
indakaterol/glikopironij
2.
NAVEDBA ENE ALI VEČ UČINKOVIN
Ena kapsula vsebuje 110 mikrogramov indakaterola in 50 mikrogramov
glikopironija. Količina
inhaliranega indakaterola je 85 mikrogramov (kar ustreza 110
mikrogramom indakaterolijevega
maleata), inhaliranega glikopironija pa 43 mikrogramov (kar ustreza 54
mikrogramom
glikopironijevega bromida).
3.
SEZNAM POMOŽNIH SNOVI
Vsebuje tudi: laktozo in magnezijev stearat.
Za več podatkov glejte navodilo za uporabo.
4.
FARMACEVTSKA OBLIKA IN VSEBINA
prašek za inhaliranje, trda kapsula
Skupno pakiranje: 96 kapsul (4 pakiranja po 24 x 1) in 4 inhalatorji.
Skupno pakiran
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
PRILOGA I
POVZETEK GLAVNIH ZNAČILNOSTI ZDRAVILA
2
1.
IME ZDRAVILA
Ulunar Breezhaler 85 mikrogramov/43 mikrogramov prašek za
inhaliranje, trde kapsule
2.
KAKOVOSTNA IN KOLIČINSKA SESTAVA
Ena kapsula vsebuje 143 mikrogramov indakaterolijevega maleata, kar
ustreza 110 mikrogramom
indakaterola, in 63 mikrogramov glikopironijevega bromida, kar ustreza
50 mikrogramom
glikopironija.
En odmerek, ki pride skozi ustnik inhalatorja, vsebuje 110 mikrogramov
indakaterolijevega maleata,
kar ustreza 85 mikrogramom indakaterola, in 54 mikrogramov
glikopironijevega bromida, kar ustreza
43 mikrogramom glikopironija.
Pomožna(e) snov(i) z znanim učinkom:
Ena kapsula vsebuje 23,5 mg laktoze (v obliki monohidrata).
Za celoten seznam pomožnih snovi glejte poglavje 6.1.
3.
FARMACEVTSKA OBLIKA
prašek za inhaliranje, trda kapsula (prašek za inhaliranje)
Kapsule z rumenim prozornim pokrovčkom in brezbarvnim prozornim
telesom. Kapsule vsebujejo bel
do skoraj bel prašek in imajo na telesu kapsule pod dvema modrima
črtama modro tiskano oznako
“IGP110.50”, na pokrovčku pa črno tiskan zaščitni znak družbe
(
).
4.
KLINIČNI PODATKI
4.1
TERAPEVTSKE INDIKACIJE
Zdravilo Ulunar Breezhaler je indicirano kot vzdrževalno
bronhodilatatorno zdravljenje za lajšanje
simptomov pri odraslih bolnikih s kronično obstruktivno pljučno
boleznijo (KOPB).
4.2
ODMERJANJE IN NAČIN UPORABE
Odmerjanje
Priporočeni odmerek je inhalacija vsebine ene kapsule enkrat na dan z
uporabo inhalatorja Ulunar
Breezhaler.
Zdravilo Ulunar Breezhaler je priporočeno uporabiti vsak dan ob istem
času. V primeru izpuščenega
odmerka je treba zdravilo vzeti čimprej še isti dan. Bolnikom je
treba naročiti, naj ne vzamejo več kot
enega odmerka v istem dnevu.
Posebne skupine bolnikov
_Populacija starejših _
Starejši bolniki (stari 75 let ali več) lahko uporabljajo zdravilo
Ulunar Breezhaler v priporočenem
odmerku.
3
_Okvara ledvic _
Bolniki z blago do zmerno okvaro ledvic lahko uporabljajo zdravilo
Ulunar Breezhaler v
priporočenem odmerku. Bolniki s hud
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 24-02-2023
Summary of Product characteristics Summary of Product characteristics Bulgarian 24-02-2023
Public Assessment Report Public Assessment Report Bulgarian 16-05-2014
Patient Information leaflet Patient Information leaflet Spanish 24-02-2023
Public Assessment Report Public Assessment Report Spanish 16-05-2014
Patient Information leaflet Patient Information leaflet Czech 24-02-2023
Public Assessment Report Public Assessment Report Czech 16-05-2014
Patient Information leaflet Patient Information leaflet Danish 24-02-2023
Public Assessment Report Public Assessment Report Danish 16-05-2014
Patient Information leaflet Patient Information leaflet German 24-02-2023
Public Assessment Report Public Assessment Report German 16-05-2014
Patient Information leaflet Patient Information leaflet Estonian 24-02-2023
Public Assessment Report Public Assessment Report Estonian 16-05-2014
Patient Information leaflet Patient Information leaflet Greek 24-02-2023
Public Assessment Report Public Assessment Report Greek 16-05-2014
Patient Information leaflet Patient Information leaflet English 24-02-2023
Public Assessment Report Public Assessment Report English 16-05-2014
Patient Information leaflet Patient Information leaflet French 24-02-2023
Public Assessment Report Public Assessment Report French 16-05-2014
Patient Information leaflet Patient Information leaflet Italian 24-02-2023
Public Assessment Report Public Assessment Report Italian 16-05-2014
Patient Information leaflet Patient Information leaflet Latvian 24-02-2023
Public Assessment Report Public Assessment Report Latvian 16-05-2014
Patient Information leaflet Patient Information leaflet Lithuanian 24-02-2023
Summary of Product characteristics Summary of Product characteristics Lithuanian 24-02-2023
Public Assessment Report Public Assessment Report Lithuanian 16-05-2014
Patient Information leaflet Patient Information leaflet Hungarian 24-02-2023
Summary of Product characteristics Summary of Product characteristics Hungarian 24-02-2023
Public Assessment Report Public Assessment Report Hungarian 16-05-2014
Patient Information leaflet Patient Information leaflet Maltese 24-02-2023
Public Assessment Report Public Assessment Report Maltese 16-05-2014
Patient Information leaflet Patient Information leaflet Dutch 24-02-2023
Public Assessment Report Public Assessment Report Dutch 16-05-2014
Patient Information leaflet Patient Information leaflet Polish 24-02-2023
Public Assessment Report Public Assessment Report Polish 16-05-2014
Patient Information leaflet Patient Information leaflet Portuguese 24-02-2023
Summary of Product characteristics Summary of Product characteristics Portuguese 24-02-2023
Public Assessment Report Public Assessment Report Portuguese 16-05-2014
Patient Information leaflet Patient Information leaflet Romanian 24-02-2023
Public Assessment Report Public Assessment Report Romanian 16-05-2014
Patient Information leaflet Patient Information leaflet Slovak 24-02-2023
Public Assessment Report Public Assessment Report Slovak 16-05-2014
Patient Information leaflet Patient Information leaflet Finnish 24-02-2023
Public Assessment Report Public Assessment Report Finnish 16-05-2014
Patient Information leaflet Patient Information leaflet Swedish 24-02-2023
Public Assessment Report Public Assessment Report Swedish 16-05-2014
Patient Information leaflet Patient Information leaflet Norwegian 24-02-2023
Summary of Product characteristics Summary of Product characteristics Norwegian 24-02-2023
Patient Information leaflet Patient Information leaflet Icelandic 24-02-2023
Summary of Product characteristics Summary of Product characteristics Icelandic 24-02-2023
Patient Information leaflet Patient Information leaflet Croatian 24-02-2023
Public Assessment Report Public Assessment Report Croatian 16-05-2014